Abstract: A fluid delivery device includes a housing having a bottom surface configured to be coupled to the skin surface. The fluid delivery device includes a cartridge prefilled with a fluid and configured to be inserted into the housing. The cartridge has a septum configured to be generally perpendicular to the bottom surface when the cartridge is inserted in the housing. The fluid delivery device includes a needle assembly that has a needle that includes a fluid coupling end and a delivery end. The fluid coupling end of the needle is fluidly disengaged from the cartridge in an initial position. The delivery end of the needle extends past the plane of the bottom surface and the fluid coupling end of the needle extends through the septum in a deployed position.

Abstract: Implantable gas delivery device and methods, systems, and devices including same. According to one embodiment, the implantable gas delivery device includes a porous core that permits facile transport of gas throughout its open volume. The porous core has sufficiently high tensile strength to withstand pressurization without significant deformation. The porous core is generally planar and is shaped to include a pair of opposing surfaces and a periphery. Diffusion membranes are fixed to the two opposing surfaces of the porous core. A gas supply tube has one end inserted into the porous core and another end connectable to a gas source. The periphery of the porous core is sealed gas-tight, either with a gasket or by sealing the porous core and/or diffusion membranes. The device may be used to deliver a gas to an implanted cell capsule or to native cells or tissues or may be used to expel waste gas.

Abstract: Systems and methods can include wearable, non-invasive ultrasound modalities for treating a variety of medical conditions, including but not limited to peripheral vascular disease. The modality could be therapeutic ultrasound (TUS), and be configured to promote angiogenesis within a patient via stimulation of cavitation and shear stress, among other mechanisms.

Abstract: A syringe pump includes a lead screw, a motor, and a sliding block assembly. The lead screw has threads and the motor is coupled to the lead screw to rotate it. The half-nut housing has a half nut and a barrel cam. The half nut is disposed within the half-nut housing. The half nut has half-nut threads at an end adjacent to the lead screw void. The half nut engages or disengages with the threads of the lead screw. The half nut includes a half-nut cam-follower surface and a half nut slot. The barrel cam is disposed within the half-nut housing and engages with the half-nut cam-follower surface. The barrel cam includes a pin to fit within the half nut slot such that the barrel cam rotates between a first position and a second position to actuate the half nut between the engagement position and the disengagement position, respectively.

Abstract: A method for producing an underpants-type disposable diaper including a stretchable region stretchable at least in one direction in an outer body. The stretchable region is formed by stacking an elastic film between a first sheet layer composed of a nonwoven fabric and a second sheet layer composed of a nonwoven fabric. When the elastic film is stretched in the stretching and contracting direction, the first sheet layer and the second sheet layer are joined via through holes formed in the elastic film at a large number of sheet bond portions arranged at intervals in each of a stretching and contracting direction and a direction orthogonal thereto, and in the sheet bond portions, the first sheet layer and the second sheet layer (20B) are joined at least by a melted and solidified material of the elastic film among the first sheet layer and the second sheet layer.

Abstract: A system and method is provided for detecting fluid low-volume and occlusion in a device using force sensing resistor (FSR) sensor. One or more force sensing resistors are positioned in communication with a fluid channel at one or more of a pump intake and pump outlet to detect pressure in the fluid channel. The pressure is detected through communication with the force sensing resistor and indicates an irregular system condition including but not limited to, fluid low-volume level and occlusion. Also provided are a fluid flow sensor (e.g., FSR or MEMS sensor) disposed relative to an embedded fluid channel in the base of a wearable medicine delivery pump.

Abstract: According to the present invention, there are provided a chamber for transplantation, as a planar chamber for transplantation which has a structure in which membranes for immunoisolation face each other, and which is capable of stably enclosing a biological constituent, including a membrane for immunoisolation at a boundary between an inside and an outside of the chamber for transplantation, in which the membranes for immunoisolation which face each other have joint portions that are joined to each other, an interior space includes a point at a distance of 10 mm or longer from any position of the joint portion, and the membrane for immunoisolation has flexibility that allows a distance of 1 mm to 13 mm as the following distance: in a case where a portion of 10 mm from a side surface of one short side of a 10 mm×30 mm rectangular test piece of the membrane for immunoisolation is vertically sandwiched between flat plates, and the flat plates are placed horizontally, a distance between a horizontal plane includi

Abstract: An osmotic food production system designed to produce fruits, vegetables, and freshwater from urine or saltwater. In some embodiments the osmotic food production system also produces oxygen. In some embodiments, the osmotic food production system is portable and capable of transporting on a vehicle capable of space travel. Embodiments of the present invention can be used to address the existing problems of food production, waste disposal/utilization, oxygen generation, and water conservation in an efficient way to allow for prolonged space travel or colonization of distant planets and moons.

Abstract: A patch-sized fluid delivery device may include a reusable portion and a disposable portion. The disposable portion may include components that come into contact with the fluid, while the reusable portion may include only components that do not come into contact with the fluid. Redundant systems, such as redundant controllers, power sources, motor actuators, and alarms, may be provided. Alternatively or additionally, certain components can be multi-functional, such a microphones and loudspeakers that may be used for both acoustic volume sensing and for other functions and a coil that may be used as both an inductive coupler for a battery recharger and an antenna for a wireless transceiver. Various types of network interfaces may be provided in order to allow for remote control and monitoring of the device.

Abstract: A wearable infusion port for infusing a fluid includes a first housing that defines an inlet port to receive the fluid, and a second housing coupled to the first housing. The second housing is to be coupled to an anatomy. The wearable infusion port includes a valve assembly fluidly coupled to the inlet port, and the valve assembly is movable from a closed state to an opened state to dispense the fluid. The wearable infusion port includes a cannula assembly extending through the first housing and the second housing, and the cannula assembly includes a cannula fluidly coupled to the valve assembly. The cannula is to be coupled to the anatomy. The wearable infusion port includes a flow sensor fluidly coupled to the inlet port and the cannula. The flow sensor is fluidly coupled upstream from the cannula to observe an amount of fluid received by the cannula.

Abstract: The present disclosure is in the field of gastroretentive dosage forms. A gastroretentive dosage form for extended retention in a stomach is provided.

Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering therapeutic agents within the GI tract such as neutralizing proteins (NP) particularly antibodies which neutralize interleukins. Many embodiments provide a swallowable device e.g., a capsule for delivering various agents into the intestinal wall (IW). Embodiments also provide agent preparations that are configured to be contained within the capsule, advanced from the capsule into the IW and degrade to release the agent into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW.

Abstract: An elastic film stretchable structure in which an elastic film is stacked between a first sheet layer having air permeability and a second sheet layer having air permeability, the first sheet layer and the second sheet layer are bonded through bonding holes penetrating the elastic film at a number of sheet bonded portions arranged at intervals. A region having the elastic film stretchable structure has a stretchable region that is stretchable in a stretchable direction, and the stretchable region is contracted in the stretchable direction by a contraction force of the elastic film and is extensible in the stretchable direction, and vent holes are formed on the elastic film at sites where the elastic film does not overlap with the sheet bonded portions.

Abstract: The present invention provides a closed loop control method in an artificial pancreas and a system using the method, comprising sensing an activity level of a patient by at least one motion sensor and providing signals to at least one processer; then adjusting a series of related algorithms depending partly on the signals by the processer to provide more accurate and reliable data that is the basis of desirable treatment plans, and sending corresponding instructions by the processer for automatic operations of the artificial pancreas to realize a closed loop control.

Abstract: Embodiments of the present invention are directed to a liquid delivery apparatus. A non-limiting example of the apparatus includes a substrate including a cavity formed in a surface of the substrate. The apparatus can also include a membrane disposed on the surface of the substrate covering an opening of the cavity. The apparatus can also include a hydrophobic layer disposed on the membrane. The apparatus can also include a seal disposed between the membrane and the substrate, wherein the seal surrounds the opening of the cavity. The apparatus can also include an electrode layer coupled to the membrane.

Abstract: This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices.

Abstract: An injector has a cartridge door movable between a fully closed position and a fully open position. A power supply is employed to power at least one power-operated component of the injector. A power supply circuit electrically connects the power supply with the at least one power-operated component. An electrically insulated arm is movable from a first state, in which the electrically insulated arm electrically disconnects the power supply from the circuit, to a second state, in which the electrically insulated arm connects the power supply with the circuit to provide power to the at least one power-operated component. The insulated arm is coupled to the cartridge door and initially positioned in the first state thereof in the fully closed position of the cartridge door, whereby movement of the cartridge door out of the fully closed position toward the fully open position moves the arm to the second state thereof.

Abstract: A method of in vivo conditioning of an indwelling sensor to reduce run-in time, (stabilization time) comprising: a) applying a first potential to the sensor and measuring a first current at the first potential; b) applying a second potential to the sensor and measuring a second current at the second potential; c) determining a relationship of the first current measured to the second current measured; repeating a, b, and c until the relationship between the first current measured and the second current measured has stabilized, thereby reducing sensor run-in time.

Abstract: Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and/or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and/or degraded within the GI tract.

Abstract: Disclosed herein is a system for facilitating administration of a pharmaceutical product. Accordingly, the system may include at least one sensor, a storage device, a processing device, and a Mobile Administration Interlocking Device (MAID). Further, the at least one sensor may be disposed on body of a user. Further, the at least one sensor may be configured for generating at least one physiological data associated with the body. Further, the storage device may be configured for storing at least one dosage data. Further, the at least one dosage data may be prescribed by a medical professional. Further, the processing device may be communicatively coupled with the at least one sensor. Further, the processing device may be communicatively coupled with the storage device. Further, the MAID may be configured for provisioning the pharmaceutical product to the user. Further, the MAID may be communicatively coupled with the processing device.

Abstract: The present disclosure relates to a delivery device capable of delivering compositions. In some embodiments, the delivery device may deliver compositions to the gastrointestinal tract. In some embodiments, the compositions contain active drug substances. In some embodiments, the active drug substances are low permeable active drug substances.

Abstract: The present disclosure is directed to a natural-based liquid composition for use with electronic vaporizing devices. The present disclosure is also directed to electronic vaporizing devices for using such composition. In one embodiment, the liquid compositions are water-based and are substantially free of propylene glycol and vegetable glycerin. In a preferred embodiment, the compositions may be augmented to include additives such as medicines, wellness elements, supplements, recreational elements, and natural elements performing the role of emulsifiers. The present disclosure is also directed to electronic vaporizing devices for vaporizing a natural-based liquid composition. The electronic vaporizing device may include the functionality to create specified or custom mixtures of a vaporizable material for the vaporizing thereof.

Abstract: Disclosed is an apparatus for measuring bio signals. The apparatus for measuring bio signals includes: a sensor module configured to include a needle sensor to be inserted into the skin; and a main body to which the sensor module is separably coupled, and which is configured to include a controller controlling the sensor module to measure a bio signal through the needle sensor, once the sensor module is coupled.

Abstract: Provided are a storage container, a microneedle unit, a storage container group, and a method of producing a microneedle unit that enable protection of a microneedle array before puncture and realization of a puncturing property of the microneedle array using a simple member. The storage container, which stores a microneedle array including a sheet having a first surface and a second surface that oppose each other and a plurality of needles arranged on the first surface of the sheet, includes a first member having an edge portion that defines a second opening and a second member having a depression, in which the microneedle array is stored by superimposing the second member on the first member, and the second member and the first member are deformed by applying a force to the second member in a state in which the second member is superimposed on the first member, and the needles of the microneedle array are allowed to protrude from the first member to puncture a skin.

Abstract: A method of atraumatic medication pellet delivery using an atraumatic trocar apparatus is described. The atraumatic trocar apparatus includes a cannula and an obturator. The method includes receiving the obturator by the cannula, wherein the obturator passes through the interior passage and exits through the anterior cannula opening so that the obturator anterior rounded tip extends past the anterior cannula end and at least one opening proximate to the anterior rounded tip also extends past the anterior cannula end. The method includes inserting the atraumatic trocar through an incision into subcutaneous tissue along an insertion path to an insertion length. Additionally, the method includes inserting one or more medication pellet into the medication slot of the inserted cannula and delivering the medication pellet(s) through the interior passage of the cannula to a subcutaneous delivery site by inserting the obturator into the posterior opening of the cannula.

Abstract: An intravenous (IV) fluid delivery system include an IV bag and a fluid delivery device. The IV bag is made of many fluidic channels that keep the fluid distributed across the bag such that the bag may be easily and comfortably wrapped around the arm and shoulder of a person. The fluid delivery device includes a processor controlled electromechanical delivery mechanism that controls a positive displacement pump. The pump moves the fluid into a tube and a needle that is connected to a person's vein. The processor repeatedly turns the pump on or off to gradually transfer the fluid from the IV bag into the person's vein. The processor controls the granularity of the fluid delivery, where the fluid may be administered in a fluid delivery period, the fluid delivery may then be stopped in a subsequent fluid stoppage period, followed by other fluid delivery periods.

Abstract: Certain embodiments comprise administering a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance, and, optionally, a linker. In some such embodiments, the linker may be configured to degrade.

Abstract: A wearable injector for automated delivery of biologic drugs that solves the problem of high volume and high viscosity drug administration by providing a device that can be worn by the patient through use of an adhesive patch to deliver the medication slowly over extended periods of time.

Abstract: Infusion systems, infusion devices, and related operating methods are provided. An exemplary method of operating an infusion device to deliver a bolus amount of fluid influencing a physiological condition in a body of a user involves identifying, based on measurement values for the physiological condition, a residual value for the physiological condition resulting from the bolus amount of the fluid and determining an updated ratio for a subsequent bolus by adjusting an initial ratio influencing the bolus amount to compensate for the residual value. The updated ratio may be stored in a data storage element for use in determining a subsequent bolus amount in lieu of the initial ratio value.

Abstract: A surgical stapling device includes a tool assembly that has a staple cartridge that includes a perfluorocarbon (hereinafter “PFC”) solution that is injected into tissue when the surgical stapling device is fired to improve oxygenation of tissue being treated. In aspects of the disclosure, the tool assembly of the surgical stapling device includes a staple cartridge that has staples that are supported on pushers and an actuation sled that is movable through the staple cartridge into engagement with the pushers to eject staples from the staple cartridge. In certain aspects of the disclosure, the PFC solution is contained within the pushers of a staple cartridge of the tool assembly and the actuation sled includes protrusions that engage the pushers to eject the PFC solution from the pushers when the stapling device is fired.

Abstract: Methods, compositions, and devices for enhancing transdermal delivery of large agents.

Abstract: An implantable device contains a drug or biosensing compound, protected from the external environment within a human body by several barriers which are broken upon activation of the device through electrothermal, chemical, and mechanical processes. The device allows accurate and repeated dosing within a human body, thus reducing the number of implantation procedures required. This device extends the lifetime of a biosensor, reducing the number of implantation procedures required.

Abstract: A system and method for identifying a stimulation location on a nerve is disclosed. The system includes an image-based navigation interface used to facilitate advancing a stimulation element within a patient body toward a target nerve stimulation site. Using the system one determines, separately for each potential target nerve stimulation site, a neuromuscular response of muscles produced upon applying a stimulation signal at the respective separate potential target stimulation sites. The image-based navigation interface is configured to display a graphic identification of which muscles were activated for each respective potential target nerve stimulation site upon applying the stimulation signal.

Abstract: A method of securing an antenna assembly to a wearable article includes positioning a template carrying a first antenna at a desired position on the wearable article worn on a body of a patient. The desired position is in proximity to a wireless tissue stimulator implanted within the body. The method further includes marking a location of the desired position of the template against the wearable article, securing a first attachment feature to the wearable article at a mark located at the desired position, and attaching the antenna assembly to the wearable article at the first attachment feature. The antenna assembly includes a second antenna configured to send a signal carrying electrical energy to the wireless tissue stimulator and a housing carrying the second antenna. The housing includes a second attachment feature configured to engage the first attachment feature for positioning the second antenna adjacent the body.

Abstract: Ingestible devices with a relatively large payload volume or sample volume, as well as related components, systems and methods, are disclosed.

Abstract: A medicament delivery device includes a device housing for placing on the skin of a patient, the housing including a needle aperture; a needle for injecting a medicament, the needle arranged to pass through the needle aperture; and sensors configured to provide a signal when the housing is placed on the skin of the patient. The sensors are arranged around the needle aperture.

Abstract: A blood glucose control system is configured to modify therapy provided to a subject. The system can cause first therapy to be delivered by the blood glucose control system to a subject during a first therapy period. The first therapy can be delivered based at least in part on a first value of a control parameter used by a control algorithm to generate a dose control signal. The system can determine a first effect corresponding at least in part to the first therapy and autonomously generate a second value of the control parameter. The system can cause second therapy to be delivered by the blood glucose control system to the subject during a second therapy period, wherein the second therapy is delivered based at least in part on the second value of the control parameter.

Abstract: A tool has an outer assembly, which includes a deployment tube, extending around, and moveable with respect to an inner assembly of the tool; the inner assembly includes a single pull wire and a distal member configured to engage an end of an implantable medical device. The deployment tube includes an articulating segment located just proximal to an enlarged distal-most portion, which contains the device and the distal member. Relatively soft and stiff sections of a composite sidewall define the articulating segment and extend alongside one another, such that, when the pull wire is actuated, the composite sidewall causes bending of the segment in two directions. A handle assembly of the tool includes a control member for the pull wire, and may further include a flushing subassembly that has a connector port located at an end of the handle assembly that is opposite a proximal port of the handle.

Abstract: An embodiment of the invention is a shape memory polymer (SMP) foam designed to recover its original shape through exposure to a solvent. Thermo-responsive SMPs are polymers designed to maintain a programmed secondary shape until heated above their transition temperature, upon which the polymer recovers its original, or primary, shape. The thermo-responsive SMP foam is programmed to its secondary shape prior to use, typically compression of the foam to a small volume, and remains in this programmed shape until exposed to a selected solvent such as dimethyl sulfoxide or ethyl alcohol. Upon exposure to the solvent, the transition temperature of the SMP foam decreases below the temperature of the environment and the SMP foam actuates to its primary shape. The SMP foam is tailored to actuate upon exposure to specific solvents while minimizing or preventing actuation when exposed to water or other solvents.

Abstract: A method includes providing a medication delivery vehicle comprising a reservoir with a seal formed thereon and a cantilevered beam micro-machined from a layer of material and coupled to the reservoir, the cantilevered beam comprising a tip for puncturing the seal, applying an electric field to the cantilevered beam that impels the tip forward and causes the tip to break through the seal of the reservoir, and changing the electric field to impel the micro-machined tip backward and thereby release a medication from the reservoir. A computer program product and computer system corresponding to the method are also disclosed.

Abstract: An ingestible pill is provided that includes an enteric coating and a medication-delivery device, which includes (a) a patch having upper and lower surfaces that face in generally opposite directions, and (b) needles. The patch is disposed within the enteric coating, folded so as to define one or more creases, which define respective inner and outer crease sides, wherein at least 50% of the needles are coupled to the patch along the inner crease sides. The patch is configured to assume, after the enteric coating dissolves, an expanded shape, in which the patch has an outer perimeter. Other embodiments are also described.

Abstract: A blood glucose control system is configured to modify therapy provided to a subject. The system can cause first therapy to be delivered by the blood glucose control system to a subject during a first therapy period. The first therapy can be delivered based at least in part on a first value of a control parameter used by a control algorithm to generate a dose control signal. The system can determine a first effect corresponding at least in part to the first therapy and autonomously generate a second value of the control parameter. The system can cause second therapy to be delivered by the blood glucose control system to the subject during a second therapy period, wherein the second therapy is delivered based at least in part on the second value of the control parameter.

Abstract: An inner ear fluid circulation system includes an implantable circulation pump that has a pump inlet and a pump outlet both in fluid communication with inner ear fluid of an implanted patient. The circulation pump is configured to drive the inner ear fluid in from the pump inlet and out through the pump outlet. A pump controller is coupled to the circulation pump and one or more sensing elements for measurement of one or more fluid conditions within the inner ear of the implanted patient, and is configured to control operation of the circulation pump as a function of the measured one or more fluid conditions. Also disclosed is a cochlear implant arrangement and a vestibular implant arrangement comprising such a fluid circulation system.

Abstract: A blood glucose control system is configured to modify therapy provide to a subject and determine whether the modified therapy results in a statistically significant improvement in glycemic control. The system obtains glycemic control information resulting from delivery of first therapy using a first value of a control parameter and determines a first effect corresponding to the first therapy. The control parameter is set to a second value that differs from the first value. The system obtains glycemic control information resulting from the delivery of the second therapy using the second value of the control parameter and determines a second effect corresponding to the second therapy. The system can perform a comparative assessment and determine whether the second value for the control parameter results in a statistically significant improvement in glycemic control for the subject.

Abstract: This invention relates to novel extended release pharmaceutical compositions of levetiracetam and preparations and characterizations thereof. This invention further relates to using these extended release pharmaceutical compositions of levetiracetam for the treatment of cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof.

Abstract: An intragastric balloon device including a deformable material is in an ingestible form for delivery to a stomach of a patient, expands in response to stimuli in the stomach, and degrades within a limited duration (such as 16 hours or some other value between 2 hours and 72 hours) to diminish to passable form in which remains of the intragastric balloon device are passable from the stomach. In an illustrative example, the deformable material is composed of silicone coated with parylene and encloses perfluoropentane fluid that transitions from liquid to gas due to stomach temperature to inflate the balloon in the stomach and occupy space in the stomach until a fuse of methacrylate erodes to unblock a vent conduit to permit escape of the perfluoropentane for deflating the balloon to diminish to passable form.

Abstract: Provided herein is an implant for delivering a hydrophobic active agent to a target tissue. The implant may include a scaffold defining a first surface and a second surface opposite the first surface, wherein the scaffold is substantially impermeable to a hydrophobic active agent, and a silicone tubing having a wall permeable to the active agent, wherein a first length of the silicone tubing is affixed to the first surface of the scaffold, wherein the two ends of the silicone tubing extend from the first surface, and wherein a path outlined by a second length of the tubing within the first length is circuitous. Also provided is a method of using the implant to locally deliver a hydrophobic active agent to a target tissue, and kits that find use in performing the present method.

Abstract: A frequency sensor comprises a surface functionalized with a reactant sensitive to an analyte and a vibration detector coupled to the functional surface to detect a frequency of a fluid having the analyte and located on the functional surface during vibration thereof. The frequency sensor comprises a measurement circuitry coupled to the vibration detector to determine a frequency shift over time of the detected frequency, wherein the frequency shift corresponds to the presence of the analyte which has reacted with the reactant.

Abstract: A digital biomedical device includes a substrate forming a cavity, a seal formed around the cavity, a lid coupled to the substrate by the seal, a reactive metal structure comprising a plurality of metal layers, wherein the reactive metal structure is a component of at least one of the substrate and the lid, a metal trace configured to initiate a self-propagating reaction between the plurality of metal layers of the reactive metal structure and release contents of the cavity, and a power supply configured to apply an electric current to the metal trace.

Abstract: A method of atraumatic medication pellet delivery using an atraumatic trocar apparatus is described. The atraumatic trocar apparatus includes a cannula and an obturator. The method includes receiving the obturator by the cannula, wherein the obturator passes through the interior passage and exits through the anterior cannula opening so that the obturator anterior rounded tip extends past the anterior cannula end and at least one opening proximate to the anterior rounded tip also extends past the anterior cannula end. The method includes inserting the atraumatic insertion trocar through an incision into subcutaneous tissue along an insertion path to an insertion length. Additionally, the method includes inserting one or more medication pellet into the medication slot of the inserted cannula and delivering the medication pellet(s) through the interior passage of the cannula to a subcutaneous delivery site by inserting the delivery obturator into the posterior opening of the cannula.